Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy
Ver/ abrir
Use este enlace para citar
http://hdl.handle.net/2183/39049
A non ser que se indique outra cousa, a licenza do ítem descríbese como Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0)
Coleccións
- INIBIC-ICATC - Artigos [178]
Metadatos
Mostrar o rexistro completo do ítemTítulo
Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathyAutor(es)
Data
2024-03-04Cita bibliográfica
Grogan M, Davis MK, Crespo-Leiro MG, Sultan MB, Gundapaneni B, Angeli FS, Hanna M. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy. Eur J Heart Failure. 2024;26(3):612-615.
Resumo
[Abstract] Aims. To evaluate the effect of long-term tafamidis treatment on health-related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension (LTE) study.
Methods and results. We examined change from baseline in Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) and clinical summary (KCCQ-CS) scores in patients who received tafamidis meglumine 80 mg for 30 months in ATTR-ACT and tafamidis (meglumine 80 mg or bioequivalent free acid 61 mg) for 30 months in the LTE study, and in patients who received placebo for 30 months in ATTR-ACT and tafamidis for 30 months in the LTE study. In ATTR-ACT, 176 and 177 patients were randomized to tafamidis 80 mg and placebo, respectively. Patients who continuously received tafamidis had a 6- to 7-point reduction in least squares (LS) mean (standard error) KCCQ-OS and KCCQ-CS scores at month 30 (−6.25 [1.53] and −7.48 [1.39]), with little or no further decline over the next 30 months (−5.92 [1.77] and −9.21 [1.88] at month 60). Patients who received placebo in ATTR-ACT had a 20-point reduction in LS mean KCCQ-OS and KCCQ-CS scores at month 30 (−19.60 [1.94] and −19.90 [2.01]), but the decline slowed after initiating tafamidis (−24.70 [3.04] and −25.30 [3.36] at month 60).
Conclusion. Tafamidis reduced HRQoL decline in patients with ATTR-CM. Patients continuously treated with tafamidis for 60 months demonstrated stabilized HRQoL. In patients who initially received placebo in ATTR-ACT, tafamidis reduced the decline in HRQoL during the LTE study.
Descrición
Short report
Versión do editor
Dereitos
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0)
ISSN
1879-0844